Trials / Unknown
UnknownNCT05294835
Ketamine and Epigenetic Aging
Impact of Ketamine on Epigenetic Age (IKEA)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- TruDiagnostic · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.
Detailed description
Subjects with MDD or PTSD will have a series of six ketamine infusions over two to three weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine | ketamine infusion |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2022-03-24
- Last updated
- 2022-09-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05294835. Inclusion in this directory is not an endorsement.